Mosunetuzumab (BTCT-4465A) is a fully humanized, full-length immunoglobulin G1 (IgG1) T-cell-dependent bispecific (TDB) antibody designed to concurrently target CD20 on B cells and CD3 on T cells. This bispecific nature allows Mosunetuzumab to redirect T cells to engage and eliminate malignant B cells. It is primarily utilized in research focused on relapsed or refractory B-cell non-Hodgkin lymphomas (B-NHLs), providing a valuable tool for studies aimed at understanding and potentially treating these conditions.
Mosunetuzumab (BTCT-4465A) is a fully humanized, full-length immunoglobulin G1 (IgG1) T-cell-dependent bispecific (TDB) antibody designed to concurrently target CD20 on B cells and CD3 on T cells. This bispecific nature allows Mosunetuzumab to redirect T cells to engage and eliminate malignant B cells. It is primarily utilized in research focused on relapsed or refractory B-cell non-Hodgkin lymphomas (B-NHLs), providing a valuable tool for studies aimed at understanding and potentially treating these conditions.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
